证券代码:300147 证券简称: 香雪制药 公告编号:2023—048 广州市香雪制药股份有限公司 关于公司被申请强制执行的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次被列入申请强制执行的情况 公司在获悉上述事项后已向广州市中级人民法院核实相关情况，暂未收到广 州市中级人民法院出具的执行相关文书，根据执行标的金额初步判断，该执行案 件申请人为中国银行股份有限公司广州开发区分行（以下简称"中行开发区分 行"）。公司与中行开发区分行于 2021 年 6 月、2022 年 5 月分别签订了《流动 资金借款合同》，因公司出现流动性收缩导致未能按时履行还款义务，双方协商 无果，其向广州仲裁委员会对公司提起仲裁，广州仲裁委员会裁决后，其向广州 市中级人民法院对公司申请了强制执行。 二、对公司的影响 近日，广州市香雪制药股份有限公司（以下简称"公司"）通过中国执行信 息公开网（http://zxgk.court.gov.cn）公示信息查询得知公司依法被申请强制 执行。具体情况如下： 被执行人名称 广州市香雪制药股份有限公司 广州市香雪制药股份有限公司 执 ...

广州市香雪制药股份有限公司 单位：万元 | | | | | | 2023 年半年 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 占用方与上市公 | 上市公司核算 | 2023 年期初 | 度占用累计 | 2023 年半年 | 2023 年半年 | 2023 年半年 | | | | 非经营性资金占用 | 资金占用方名称 | 司的关联关系 | 的会计科目 | 占用资金余 | 发生金额 | 度占用资金的 | 度偿还累计 | 度末占用资 | 占用形成原因 | 占用性质 | | | | | | 额 | （不含利 | 利息（如有） | 发生金额 | 金余额 | | | | | | | | | 息） | | | | | | | 控股股东、实际控制 | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | - | - | - | - | - | - | - | | 前控股股东、实际控 | | | | | | | | ...

证券代码:300147 证券简称: 香雪制药 公告编号: 2023-047 广州市香雪制药股份有限公司 2023 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无变更、否决议案的情况。 2、本次股东大会采取现场投票与网络投票表决相结合的方式召开。 一、会议召开和出席情况 1、广州市香雪制药股份有限公司（以下简称"公司"）于 2023 年 8 月 3 日 以公告形式发出《广州市香雪制药股份有限公司关于召开 2023 年第二次临时股 东大会的通知》。 2、会议召开方式：本次股东大会采取现场投票与网络投票表决相结合的方 式。 3、会议召开日期和时间 现场会议召开日期和时间：2023 年 8 月 18 日（星期五）上午 10:00 网络投票日期和时间：2023 年 8 月 18 日。其中，通过深圳证券交易所交易 系统进行网络投票的时间为 2023 年 8 月 18 日上午 9:15-9:25、9:30-11:30，下 午 13:00-15:00；通过深圳证券交易所互联网系统投票的具体时间为 2023 年 8 ...

北京大成（广州）律师事务所 广州市天河区珠江新城珠江东路 6 号 广州周大福金融中心 14-15 层 邮编：510623 14-15F CTF Finance Centre No 6 Zhujiang East Road Tianhe District 510623, Guangzhou, China dacheng.com dentons.cn 北京大成（广州）律师事务所 关于广州市香雪制药股份有限公司 2023 年第二次临时股东大会法律意见书 编号：02-042023000032-2 号 致：广州市香雪制药股份有限公司 北京大成（广州）律师事务所(以下简称"本所")接受广州市香雪制药股份有 限公司(以下简称"公司")的委托，指派吕晖律师和徐玮盼律师出席公司 2023 年 第二次临时股东大会（以下简称"临时股东大会"），就临时股东大会的召集、召 开程序、出席会议人员资格、表决程序等相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的下列各项文件： 1．《公司章程》； 2．第九届董事会第十三次会议决议； 3．第九届监事会第九次会议决议； 4．公司独立董事出具的《广州市香雪制药股份有限公司独 ...

Financial Performance - The company's revenue for Q1 2023 was ¥588,724,855.57, a decrease of 4.07% compared to ¥613,719,586.39 in the same period last year[3] - Net profit attributable to shareholders was ¥4,536,891.13, representing a significant increase of 108.34% from a loss of ¥54,380,193.73 in the previous year[3] - The net cash flow from operating activities improved to ¥54,977,540.05, a remarkable increase of 467.27% compared to a negative cash flow of ¥14,969,306.51 in the same period last year[3] - Basic earnings per share rose to ¥0.01, up 112.50% from a loss of ¥0.08 per share in the previous year[3] - Total operating revenue for Q1 2023 was CNY 588,724,855.57, a decrease of 4.8% compared to CNY 613,719,586.39 in the same period last year[18] - The company reported a net loss of CNY 495,579,610.22, slightly improved from a loss of CNY 500,116,501.35 in the previous year[16] - The net profit for Q1 2023 was ¥8,281,817.19, a significant recovery from a net loss of ¥41,900,248.37 in the same period last year, marking a turnaround of over 119%[19] - Operating profit reached ¥15,158,572.24, compared to an operating loss of ¥41,298,471.93 in Q1 2022, indicating a strong operational improvement[19] - The company reported a total comprehensive income of ¥3,899,115.34, recovering from a comprehensive loss of ¥42,054,654.04 in the same quarter last year[20] - Basic and diluted earnings per share were both ¥0.01, compared to a loss per share of ¥0.08 in Q1 2022, indicating a positive shift in profitability[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,320,480,655.95, a slight decrease of 0.35% from ¥9,353,000,538.98 at the end of the previous year[3] - Total liabilities decreased to CNY 6,498,399,773.40 from CNY 6,534,818,771.77, a decline of 0.56%[16] - The total equity increased marginally to CNY 2,822,080,882.55 from CNY 2,818,181,767.21, reflecting stability in shareholder value[16] Cash Flow and Investments - Cash and cash equivalents decreased to CNY 142,992,750.49 from CNY 166,503,309.05, a decline of 14.1%[15] - The cash flow from operating activities generated a net inflow of ¥54,977,540.05, a significant improvement from a net outflow of ¥14,969,306.51 in Q1 2022[21] - Investment activities resulted in a net cash outflow of ¥20,344,101.11, contrasting with a net inflow of ¥282,865,481.43 in Q1 2022, highlighting a shift in investment strategy[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 56,764[8] - The largest shareholder, Guangzhou Kunlun Investment Co., Ltd., holds 23.09% of shares, with 152,709,621 shares pledged and 16,987,024 shares frozen[8] - The top ten shareholders collectively hold significant stakes, with the second-largest shareholder holding 4.06%[8] - The company has a total of 3,890,503 restricted shares at the end of the reporting period, with no shares released during the current period[9] Legal Matters - The company is involved in multiple legal disputes, including a contract dispute with a total execution amount of 58,912,000 RMB and another for 122,555,968 RMB[11] - The company has reached a settlement in a previous dispute but is facing enforcement actions due to unpaid amounts[11] - The company is committed to normal production operations while monitoring the progress of legal matters[12] Operating Costs and Expenses - The company reported a 41.33% increase in taxes and surcharges, attributed to higher tax obligations during the reporting period[6] - The company experienced a 305.87% increase in operating expenses, primarily due to an increase in estimated liabilities[6] - Total operating costs decreased to CNY 587,997,301.38 from CNY 713,529,042.61, representing a reduction of 17.6%[18] - Research and development expenses increased to CNY 17,941,867.46, up from CNY 14,074,755.90, reflecting a focus on innovation[18] - The company incurred a total of ¥6,828,584.34 in non-operating expenses, which is a significant increase from ¥1,682,436.25 in the previous year, indicating higher costs in this area[19] Inventory and Cash Management - Inventory increased to CNY 507,634,706.79 from CNY 467,074,930.98, an increase of 8.6%[15] - The cash and cash equivalents at the end of the period stood at ¥85,772,717.82, down from ¥328,374,768.80 at the end of Q1 2022, reflecting a decrease of approximately 73.9%[23] - Financing activities led to a net cash outflow of ¥75,181,381.45, compared to a net outflow of ¥111,112,301.34 in the same quarter last year, indicating improved cash management in financing[23] Profitability and Cost Management - Gross profit margin improved to 0.12% from a negative margin in the previous year, indicating better cost management[18] - Non-recurring gains and losses totaled ¥1,436,883.89, primarily due to government subsidies and asset disposal gains[4]

Financial Performance - The company achieved operating revenue of CNY 2,187,069,901.40, a decrease of 26.38% year-on-year[23]. - The net profit attributable to shareholders was CNY -533,158,456.93, an increase of 22.56% compared to the previous year[23]. - The cash flow from operating activities was CNY 227,377,262.86, down 11.72% from the previous year[23]. - The total assets at the end of 2022 were CNY 9,353,000,538.98, a decrease of 17.82% from the end of 2021[23]. - The net assets attributable to shareholders decreased by 18.35% to CNY 2,405,133,051.46 compared to the end of 2021[23]. - The basic earnings per share were CNY -0.81, an improvement of 22.12% from CNY -1.04 in the previous year[23]. - The total amount of non-recurring gains and losses for 2022 was approximately $19.95 million, a decrease from $42.11 million in 2021[29]. - The company reported a significant reduction in soft drink sales, with a 93.7% decrease in sales volume and a 100% drop in production volume[65]. - The company reported a total revenue of 3.689 billion CNY for the year 2022, reflecting a significant performance in the pharmaceutical sector[132]. - The company reported a total of 16,520,000 CNY for expected daily related transactions in 2022, with actual transactions amounting to 5,793,240 CNY for goods sold and 1,029,870 CNY for leasing[194]. Business Strategy and Operations - The company continues to focus on its core business despite challenges from the macro environment and rising raw material prices[3]. - The company emphasizes that its core competitiveness and main business have not undergone significant adverse changes[3]. - The company is focused on the modernization and industrialization of traditional Chinese medicine, supported by government policies aimed at enhancing the sector's development[32]. - The company is engaged in the research and development of T-cell immunotherapy drugs, with ongoing projects targeting soft tissue sarcoma and primary liver cancer[35]. - The company has established a comprehensive supply chain management system for the procurement of traditional Chinese medicine materials, ensuring quality and stability in supply[36]. - The company has maintained a stable product line, including antiviral oral liquids and various traditional Chinese medicine products, with no significant changes reported during the period[35]. - The company aims to modernize traditional Chinese medicine and expand its industry chain, including establishing standardized processing bases and logistics[96]. - The company is focusing on precision medicine, collaborating with medical institutions to develop clinical research projects and treatment centers[96]. - The company plans to explore new medical service models, including telemedicine and smart healthcare, to integrate resources from traditional and Western medicine[96]. - The company will focus on its core business, optimizing resource allocation to enhance scale efficiency and improve market share in the cold and cough product segments[98]. Research and Development - Ongoing clinical trials include KX02 for malignant glioma and a high-affinity TCR cell therapy for soft tissue sarcoma, indicating active R&D efforts[43][44]. - The company has established a complete TCR-T technology platform, achieving international advanced levels in tumor immunotherapy[45]. - The company’s subsidiary, Xiangxue Life Sciences, has a TCR-T cell immunotherapy product, TAEST16001, which is currently in Phase II clinical trials[57]. - The total R&D investment as a percentage of operating income increased to 6.12% from 4.60% in 2021[76]. - The company is committed to enhancing its research and development capabilities to drive innovation in the pharmaceutical industry[135]. Governance and Compliance - The company has established a governance structure that includes a board of directors, supervisory board, and management team, ensuring compliance with relevant laws and regulations[113]. - The company emphasizes the importance of information disclosure, adhering to regulations to provide accurate and timely information to investors[119]. - The company maintains good communication with investors through various channels, including performance briefings and investor visits, to keep them informed about its strategic direction and business developments[120]. - The company has received a warning from the China Securities Regulatory Commission regarding non-compliance with disclosure obligations, which highlights the need for improved governance[135]. - The company has established a compensation committee to determine the remuneration of directors and senior management based on performance and responsibilities[139]. Legal and Regulatory Issues - The company faces multiple legal disputes, including a significant lawsuit involving 300 million yuan related to investment rights and another arbitration case involving approximately 280 million yuan, which could affect its financial standing[108][109]. - The company has pledged assets such as the Yunpu plant and the Biological Island No. 1 plot to cover the amounts involved in the lawsuits, indicating a proactive approach to managing legal risks[109]. - The company has been fined 250,000 yuan for violating advertising laws, but this is not expected to have a major impact on operations[190]. - The company is actively seeking reasonable solutions for ongoing litigation and has engaged a professional legal team to protect its rights[191]. Employee and Management - The total number of employees at the end of the reporting period was 2,417[150]. - The company has a comprehensive annual training plan focusing on employee development, covering various skills and management capabilities[152]. - The company has optimized its training system to enhance employee learning efficiency and engagement through internal resources and new technologies[152]. - The company has established a performance evaluation system for senior management, with the compensation committee responsible for determining annual remuneration based on operational performance and management indicators[161]. Environmental Responsibility - The company invested approximately 1.35 million yuan in wastewater treatment, environmental testing, and solid/hazardous waste management in 2022[174]. - The company has implemented a wastewater treatment facility with a design capacity of 360 m³/d, ensuring compliance with national standards[172]. - The company reported no major environmental penalties during the reporting period[174]. - The company actively promotes green practices and resource efficiency, reflecting its commitment to environmental responsibility[175].

广州市香雪制药股份有限公司（以下简称"公司"）于 2023 年 4 月 22 日在 巨潮资讯网披露 2022 年年度报告及其摘要。为了让广大投资者更加深入全面地 了解公司 2022 年度的经营情况，公司将于 2023 年 5 月 5 日（星期五）下午 15 ：00-17：00 在深圳证券交易所提供的"互动易"平台以网络远程的方式举办 2022 年度业绩说明会，投资者可登录"互动易"网站（http://irm.cninfo.com.cn ）进入"云访谈"栏目参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长兼总经理王永辉先生、独立 董事吴杰先生、董事会秘书徐力先生、财务总监牛晓燕女士。 为充分尊重投资者、提升交流的针对性，现就公司本次年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可提前登录"互 动易"网站进入公司本次年度业绩说明会页面进行提问，公司将在年度业绩说明 会上对投资者关注的问题进行回答。欢迎广大投资者积极参与！ 特此公告。 证券代码:300147 证券简称: 香雪制药 公告编号:2023-019 广州市香雪制药股份有限公司 关于举行 2022 年度业绩网 ...

证券代码：300147 证券简称：香雪制药 编号：20140828 广州市香雪制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | | √特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ | 新闻发布会 □路演活动 | | | □现场参观 | □ 一对一沟通 | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 华泰证券股份有限公司：杨烨辉、罗毅； | | 人员姓名 | 南方基金管理有限公司：韩海峰 | | | 时间 | 2014-8-28 16:00 | 至 18:00 | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事会秘书：黄滨 | | | 员 | 副总经理：曾仑 | | | | 证券事务代表：徐力 | | | | 财务经理：卢锋 | | | ...

Group 1: Company Development Strategy - The company plans to focus on the development of traditional Chinese medicine while implementing a comprehensive strategy in the Chinese medicine resource sector, including full industry chain, full channel, and full category [2][3] - The company aims to actively expand into the cutting-edge biopharmaceutical field [3] Group 2: Clinical Research and Collaborations - The company is collaborating with Hospital 458 on a clinical research project for specific T cell adoptive immunotherapy targeting solid tumors, primarily focusing on liver cancer and non-small cell lung cancer caused by hepatitis B [3] - Phase one of the clinical trial has been completed, and data is currently being organized [3] Group 3: Mergers and Acquisitions - Mergers and acquisitions are considered a pathway for external growth and a strategic direction for the company [3][4] - The management will cautiously evaluate risks and benefits before proceeding with any mergers or acquisitions, focusing on targets that complement the company's products, technology, and channels [4] Group 4: Management Team Collaboration - The company signed an investment cooperation letter with Weng Gexin and his management team on July 10, 2015, to establish a joint venture in Beijing for prescription drug marketing [4] - The project is progressing as planned, with the company committed to timely information disclosure as per relevant regulations [4] Group 5: Financial Performance - The net profit of Bozhou Huqiao Pharmaceutical Co., Ltd. declined in the first half of 2015 due to preparations for a new GMP certification and restrictions on production capacity [4] - The decline in profit was also influenced by relevant national pharmaceutical industry policies [4]

Financial Performance - The company achieved a total revenue of 752.18 million yuan in the first half of 2015, representing a year-on-year growth of 0.77% [3] - The net profit attributable to shareholders was 93.07 million yuan, an increase of 3.76% compared to the same period last year [3] Marketing Strategy - The company is focusing on integrating marketing channels and strengthening channel management to enhance the marketing team for grassroots medical institutions [4] - Adjustments in sales strategies and market promotion are being made in response to new medical reform dynamics and drug procurement policies [4] Research and Development - Increased investment in R&D is ongoing, with a focus on accelerating the development and approval of new products [4] - The company is actively working on clinical research projects, including a phase one study on specific T cell therapy for solid tumors, with results expected around October [5] Management and Compliance - The company is enhancing production site management in accordance with the new GMP standards and has received the "Second Quality Award" from the Guangzhou Development Zone [4] - The first phase of the employee stock ownership plan was completed on June 18, 2015, and is being executed as per the asset management agreement [6] Future Plans - Mergers and acquisitions are considered a strategic direction for future growth, focusing on companies that complement the company's products, technology, and channels [6] - The company is preparing for potential growth in the second half of the year following capacity improvements and compliance with new GMP certifications [7]